{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:39:07Z","timestamp":1791545947823,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T00:00:00Z","timestamp":1586649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T00:00:00Z","timestamp":1586649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10072-020-04392-8","type":"journal-article","created":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T06:02:28Z","timestamp":1586671348000},"page":"2781-2792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study"],"prefix":"10.1007","volume":"41","author":[{"given":"Marcello","family":"Moccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Frau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogera","family":"Butera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Coghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangelo","family":"Barbero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Frontoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Groppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Giovannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubaldo","family":"Del Carro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Frasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buccafusca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Latino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Nascimbene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitalma","family":"Liotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Lanfranchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rapisarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lo Fermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Altavista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Eleopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,12]]},"reference":[{"key":"4392_CR1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s00415-018-8759-1","volume":"265","author":"D Dressler","year":"2018","unstructured":"Dressler D, Bhidayasiri R, Bohlega S, Chana P, Chien HF, Chung TM, Colosimo C, Ebke M, Fedoroff K, Frank B, Kaji R, Kanovsky P, Ko\u00e7er S, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sag\u00e1stegui-Rodr\u00edguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA (2018) Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. J Neurol 265:856\u2013862. https:\/\/doi.org\/10.1007\/s00415-018-8759-1","journal-title":"J Neurol"},{"key":"4392_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11940-017-0470-5","volume":"19","author":"Y Safarpour","year":"2017","unstructured":"Safarpour Y, Mousavi T, Jabbari B (2017) Botulinum toxin treatment in multiple sclerosis\u2014a review. Curr Treat Options Neurol 19:1\u201314. https:\/\/doi.org\/10.1007\/s11940-017-0470-5","journal-title":"Curr Treat Options Neurol"},{"key":"4392_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1586\/14737175.2015.1067607","volume":"15","author":"SG Meuth","year":"2015","unstructured":"Meuth SG, Vila C, Dechant KL (2015) Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Rev Neurother 15:909\u2013918. https:\/\/doi.org\/10.1586\/14737175.2015.1067607","journal-title":"Expert Rev Neurother"},{"key":"4392_CR4","doi-asserted-by":"publisher","unstructured":"Baude M, Nielsen JB, Gracies J-M (2018) The neurophysiology of deforming spastic paresis: a revised taxonomy. Ann Phys Rehabil Med. https:\/\/doi.org\/10.1016\/j.rehab.2018.10.004","DOI":"10.1016\/j.rehab.2018.10.004"},{"key":"4392_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/ane.12139","volume":"129","author":"J Svensson","year":"2014","unstructured":"Svensson J, Borg S, Nilsson P (2014) Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand 129:13\u201320. https:\/\/doi.org\/10.1111\/ane.12139","journal-title":"Acta Neurol Scand"},{"key":"4392_CR6","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1177\/1352458514566416","volume":"21","author":"V Stevenson","year":"2015","unstructured":"Stevenson V, Gras A, Bardos J, Broughton J (2015) The high cost of spasticity in multiple sclerosis to individuals and society. Mult Scler 21:1583\u20131592. https:\/\/doi.org\/10.1177\/1352458514566416","journal-title":"Mult Scler"},{"key":"4392_CR7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1177\/1352458518799580","volume":"24","author":"PS Rommer","year":"2018","unstructured":"Rommer PS, Eichst\u00e4dt K, Ellenberger D et al (2018) Symptomatology and symptomatic treatment in multiple sclerosis: results from a nationwide MS registry. Mult Scler 24:1657\u20131664. https:\/\/doi.org\/10.1177\/1352458518799580","journal-title":"Mult Scler"},{"key":"4392_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.msard.2015.10.007","volume":"5","author":"K Milinis","year":"2016","unstructured":"Milinis K, Tennant A, Young CA (2016) Spasticity in multiple sclerosis: associations with impairments and overall quality of life. Mult Scler Relat Disord 5:34\u201339. https:\/\/doi.org\/10.1016\/j.msard.2015.10.007","journal-title":"Mult Scler Relat Disord"},{"key":"4392_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.msard.2018.07.013","volume":"25","author":"L Barin","year":"2018","unstructured":"Barin L, Salmen A, Disanto G, Baba\u010di\u0107 H, Calabrese P, Chan A, Kamm CP, Kesselring J, Kuhle J, Gobbi C, Pot C, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR) (2018) The disease burden of multiple sclerosis from the individual and population perspective: which symptoms matter most? Mult Scler Relat Disord 25:112\u2013121. https:\/\/doi.org\/10.1016\/j.msard.2018.07.013","journal-title":"Mult Scler Relat Disord"},{"key":"4392_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00415-016-8304-z","volume":"264","author":"D Dressler","year":"2017","unstructured":"Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, Jacinto LJ, Kaji R, Ko\u00e7er S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sag\u00e1stegui-Rodr\u00edguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA (2017) Botulinum toxin therapy for treatment of spasticity in multiple sclerosis : review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J Neurol 264:112\u2013120. https:\/\/doi.org\/10.1007\/s00415-016-8304-z","journal-title":"J Neurol"},{"key":"4392_CR11","doi-asserted-by":"publisher","first-page":"I\/26","DOI":"10.1007\/s00415-006-1106-y","volume":"253","author":"M Hecht","year":"2006","unstructured":"Hecht M, Jost WH, Stuckrad-barre S, Kabus C (2006) Botulinum toxin in patients with multiple sclerosis. J Neurol 253:I\/26\u2013I\/28. https:\/\/doi.org\/10.1007\/s00415-006-1106-y","journal-title":"J Neurol"},{"key":"4392_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ane.12631","volume":"135","author":"OM R\u00f8nning","year":"2017","unstructured":"R\u00f8nning OM, Tornes KD (2017) Need for symptomatic management in advanced multiple sclerosis. Acta Neurol Scand 135:529\u2013532. https:\/\/doi.org\/10.1111\/ane.12631","journal-title":"Acta Neurol Scand"},{"key":"4392_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2017.06.015","volume":"17","author":"S Giacoppo","year":"2017","unstructured":"Giacoppo S, Bramanti P, Mazzon E (2017) Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation. Mult Scler Relat Disord 17:22\u201331. https:\/\/doi.org\/10.1016\/j.msard.2017.06.015","journal-title":"Mult Scler Relat Disord"},{"key":"4392_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.rehab.2015.06.004","volume":"58","author":"A Schnitzler","year":"2015","unstructured":"Schnitzler A, Ruet A, Baron S, Buzzi JC, Genet F (2015) Botulinum toxin A for treating spasticity in adults: costly for French hospitals? Ann Phys Rehabil Med 58:265\u2013268. https:\/\/doi.org\/10.1016\/j.rehab.2015.06.004","journal-title":"Ann Phys Rehabil Med"},{"key":"4392_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1177\/0269215513480956","volume":"27","author":"M Paoloni","year":"2013","unstructured":"Paoloni M, Giovannelli M, Leonardi L et al (2013) Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial. Clin Rehabil 27:803\u2013312. https:\/\/doi.org\/10.1177\/0269215513480956","journal-title":"Clin Rehabil"},{"key":"4392_CR16","first-page":"827","volume":"52","author":"S Paolucci","year":"2016","unstructured":"Paolucci S, Martinuzzi A, Scivoletto G, Smania N, Solaro C, Aprile I, Armando M, Bergamaschi R, Berra E, Berto G, Carraro E, Cella M, Gandolfi M, Masciullo M, Molinari M, Pagliano E, Pecchioli C, Roncari L, Torre M, Trabucco E, Vallies G, Zerbinati P, Tamburin S, Italian Consensus Conference on Pain in Neurorehabilitation (ICCPN) (2016) Assessing and treating pain associated with stroke, multiple sclerosis, cerebral palsy, spinal cord injury and spasticity. Evidence and recommendations from the italian consensus conference on pain in Neurorehabilitation. Eur J Phys Rehabil Med 52:827\u2013840","journal-title":"Eur J Phys Rehabil Med"},{"key":"4392_CR17","doi-asserted-by":"publisher","first-page":"I16","DOI":"10.1007\/s00415-006-1104-0","volume":"253","author":"WH Jost","year":"2006","unstructured":"Jost WH (2006) Botulinum toxin in multiple sclerosis. J Neurol 253:I16\u2013I20. https:\/\/doi.org\/10.1007\/s00415-006-1104-0","journal-title":"J Neurol"},{"key":"4392_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.clineuro.2010.04.010","volume":"112","author":"M Habek","year":"2010","unstructured":"Habek M, Karni A, Balash Y, Gurevich T (2010) The place of the botulinum toxin in the management of multiple sclerosis. Clin Neurol Neurosurg 112:592\u2013596. https:\/\/doi.org\/10.1016\/j.clineuro.2010.04.010","journal-title":"Clin Neurol Neurosurg"},{"key":"4392_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00702-013-1145-3","volume":"121","author":"A Schramm","year":"2014","unstructured":"Schramm A, Ndayisaba J, Auf dem Brinke M et al (2014) Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry. J Neural Transm 121:521\u2013530. https:\/\/doi.org\/10.1007\/s00702-013-1145-3","journal-title":"J Neural Transm"},{"key":"4392_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/0269215517745348","volume":"32","author":"X Fu","year":"2018","unstructured":"Fu X, Wang Y, Wang C, Wu H, Li J, Li M, Ma Q, Yang W (2018) A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clin Rehabil 32:713\u2013721. https:\/\/doi.org\/10.1177\/0269215517745348","journal-title":"Clin Rehabil"},{"key":"4392_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2340\/16501977-2245","volume":"49","author":"GE Francisco","year":"2017","unstructured":"Francisco GE, Bandari DS, Bavikatte G et al (2017) Adult spasticity international registry study: methodology and baseline patient, healthcare provider, and caregiver characteristics. J Rehabil Med 49:659\u2013666. https:\/\/doi.org\/10.2340\/16501977-2245","journal-title":"J Rehabil Med"},{"key":"4392_CR22","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1177\/1352458516643600","volume":"22","author":"S Otero-Romero","year":"2016","unstructured":"Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg S\u00f8rensen P, Thompson AJ, Vermersch P, Gold R, Montalban X (2016) Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler 22:1386\u20131396. https:\/\/doi.org\/10.1177\/1352458516643600","journal-title":"Mult Scler"},{"key":"4392_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta7010","volume":"7","author":"S Beard","year":"2003","unstructured":"Beard S, Hunn A, Wight J (2003) Treatments for spasticity and pain in multiple sclerosis. Health Technol Assess (Rockv) 7:1\u2013124","journal-title":"Health Technol Assess (Rockv)"},{"key":"4392_CR24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40271-016-0173-0","volume":"9","author":"F Bethoux","year":"2016","unstructured":"Bethoux F, Marrie RA (2016) A cross-sectional study of the impact of spasticity on daily activities in multiple sclerosis. Patient 9:537\u2013546. https:\/\/doi.org\/10.1007\/s40271-016-0173-0","journal-title":"Patient"},{"key":"4392_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1586\/14737175.2013.865880","volume":"13","author":"R Gold","year":"2013","unstructured":"Gold R, Oreja-Guevara C (2013) Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother 13:55\u201359. https:\/\/doi.org\/10.1586\/14737175.2013.865880","journal-title":"Expert Rev Neurother"},{"key":"4392_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/ene.14110","volume":"27","author":"G Comi","year":"2019","unstructured":"Comi G, Solari A, Leocani L, Centonze D, Otero-Romero S, Italian Consensus Group on treatment of spasticity in multiple sclerosis (2019) Italian consensus on treatment of spasticity in multiple sclerosis. Eur J Neurol 27:445\u2013453. https:\/\/doi.org\/10.1111\/ene.14110","journal-title":"Eur J Neurol"},{"key":"4392_CR27","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s10072-017-3078-3","volume":"38","author":"P Latino","year":"2017","unstructured":"Latino P, Castelli L, Prosperini L, Marchetti MR, Pozzilli C, Giovannelli M (2017) Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurol Sci 38:1841\u20131848. https:\/\/doi.org\/10.1007\/s10072-017-3078-3","journal-title":"Neurol Sci"},{"key":"4392_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11910-014-0463-7","volume":"14","author":"MH Cameron","year":"2014","unstructured":"Cameron MH, Bethoux F, Davis N (2014) Botulinum toxin for symptomatic therapy in multiple sclerosis. Curr Neurol Neurosci Rep 14:463. https:\/\/doi.org\/10.1007\/s11910-014-0463-7","journal-title":"Curr Neurol Neurosci Rep"},{"key":"4392_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/jnnp.68.6.707","volume":"68","author":"N Hyman","year":"2000","unstructured":"Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A, Dott C (2000) Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68:707\u2013712. https:\/\/doi.org\/10.1136\/jnnp.68.6.707","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4392_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD001332","volume":"4","author":"D Shakespeare","year":"2003","unstructured":"Shakespeare D, Boggild M, Ca Y (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Satabase Syst Rev 4:1\u201339. https:\/\/doi.org\/10.1002\/14651858.CD001332","journal-title":"Cochrane Satabase Syst Rev"},{"key":"4392_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"key":"4392_CR32","unstructured":"World Health Organization (2020) ICF Browser. http:\/\/apps.who.int\/classifications\/icfbrowser\/"},{"key":"4392_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2340\/16501977-0002","volume":"39","author":"F Khan","year":"2007","unstructured":"Khan F, Pallant JF (2007) Use of international classification of functioning, disability and health (ICF) to describe patient-reported disability in multiple sclerosis and identification of relevant environmental factors. J Rehabil Med 39:63\u201370. https:\/\/doi.org\/10.2340\/16501977-0002","journal-title":"J Rehabil Med"},{"key":"4392_CR34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3109\/11038128.2012.665475","volume":"92","author":"A Conrad","year":"2012","unstructured":"Conrad A, Coenen M, Schmalz H, Kesselring J, Cieza A (2012) Validation of the comprehensive ICF core set for multiple sclerosis from the perspective of occupational therapists. Phys Ther 92:799\u2013820. https:\/\/doi.org\/10.3109\/11038128.2012.665475","journal-title":"Phys Ther"},{"key":"4392_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00415-009-5282-4","volume":"257","author":"L Holper","year":"2010","unstructured":"Holper L, Coenen M, Weise A, Stucki G, Cieza A, Kesselring J (2010) Characterization of functioning in multiple sclerosis using the ICF. J Neurol 257:103\u2013113. https:\/\/doi.org\/10.1007\/s00415-009-5282-4","journal-title":"J Neurol"},{"key":"4392_CR36","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","volume":"92","author":"P Albrecht","year":"2019","unstructured":"Albrecht P, Jansen A, Lee J-I, Moll M, Ringelstein M, Rosenthal D, Bigalke H, Aktas O, Hartung HP, Hefter H (2019) High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 92:e48\u2013e54. https:\/\/doi.org\/10.1212\/WNL.0000000000006688","journal-title":"Neurology"},{"key":"4392_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00415-006-1106-y","volume":"253","author":"C Kabus","year":"2006","unstructured":"Kabus C, Hecht M, Japp G, Jost WH, P\u00f6hlau D, Stuckrad-Barre S, Winterholler M (2006) Botulinum toxin in patients with multiple sclerosis. J Neurol 253:26\u201328. https:\/\/doi.org\/10.1007\/s00415-006-1106-y","journal-title":"J Neurol"},{"key":"4392_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/sj.sc.3101757","volume":"43","author":"MM Adams","year":"2005","unstructured":"Adams MM, Hicks AL (2005) Spasticity after spinal cord injury. Spinal Cord 43:577\u2013586. https:\/\/doi.org\/10.1038\/sj.sc.3101757","journal-title":"Spinal Cord"},{"key":"4392_CR39","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/PHM.0000000000000970","volume":"97","author":"M Etoom","year":"2018","unstructured":"Etoom M, Khraiwesh Y, Lena F, Hawamdeh M, Hawamdeh Z, Centonze D, Foti C (2018) Effectiveness of physiotherapy interventions on spasticity in people with multiple sclerosis. A systematic review and meta-analysis. Am J Phys Med Rehabil 97:793\u2013807. https:\/\/doi.org\/10.1097\/PHM.0000000000000970","journal-title":"Am J Phys Med Rehabil"},{"key":"4392_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.pmrj.2014.09.021","volume":"7","author":"HW Walker","year":"2015","unstructured":"Walker HW, Lee MY, Bahroo LB, Hedera P, Charles D (2015) Botulinum toxin injection techniques for the management of adult spasticity. PM&R 7:417\u2013427. https:\/\/doi.org\/10.1016\/j.pmrj.2014.09.021","journal-title":"PM&R"},{"key":"4392_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.pmr.2015.07.003","volume":"24","author":"F Bethoux","year":"2015","unstructured":"Bethoux F (2015) Spasticity management after stroke. Phys Med Rehabil Clin N Am 24:625\u2013539. https:\/\/doi.org\/10.1016\/j.pmr.2015.07.003","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"4392_CR42","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/0269215507072772","volume":"21","author":"M Giovannelli","year":"2007","unstructured":"Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C (2007) Early physiotherapy after injection of botulinum toxi increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 21:331\u2013337. https:\/\/doi.org\/10.1177\/0269215507072772","journal-title":"Clin Rehabil"},{"key":"4392_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.rehab.2018.08.004","volume":"62","author":"A Picelli","year":"2019","unstructured":"Picelli A, Santamato A, Chemello E, Cinone N, Cisari C, Gandolfi M, Ranieri M, Smania N, Baricich A (2019) Adjuvant treatments associated with botulinum toxin injection for managing spasticity: an overview of the literature. Ann Phys Rehabil Med 62:291\u2013296. https:\/\/doi.org\/10.1016\/j.rehab.2018.08.004","journal-title":"Ann Phys Rehabil Med"},{"key":"4392_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3138\/ptc.2014-07","volume":"67","author":"J Cheung","year":"2015","unstructured":"Cheung J, Rancourt A, Di Poce S et al (2015) Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments. Physiother Can 67:157\u2013166. https:\/\/doi.org\/10.3138\/ptc.2014-07","journal-title":"Physiother Can"},{"key":"4392_CR45","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1136\/jnnp-2016-313260","volume":"87","author":"M Moccia","year":"2016","unstructured":"Moccia M, Palladino R, Falco A et al (2016) Google trends: new evidence for seasonality of multiple sclerosis. J Neurol Neurosurg Psychiatry 87:1028\u20131029. https:\/\/doi.org\/10.1136\/jnnp-2016-313260","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4392_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/1352458519851247","volume":"26","author":"F Capone","year":"2020","unstructured":"Capone F, Collorone S, Cortese R, di Lazzaro V, Moccia M (2020) Fatigue in multiple sclerosis: the role of thalamus. Mult Scler 26:6\u201316. https:\/\/doi.org\/10.1177\/1352458519851247","journal-title":"Mult Scler"},{"key":"4392_CR47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1212\/WNL.0b013e31825dcdd9","volume":"79","author":"A Van Der Walt","year":"2012","unstructured":"Van Der Walt A, Sung S, Marriott M et al (2012) A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. Neurology 79:92\u201399. https:\/\/doi.org\/10.1212\/WNL.0b013e31825dcdd9","journal-title":"Neurology"},{"key":"4392_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrurol.2016.53","volume":"13","author":"V Ph\u00e9","year":"2016","unstructured":"Ph\u00e9 V, Chartier-Kastler E, Panicker JN (2016) Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 13:275\u2013288. https:\/\/doi.org\/10.1038\/nrurol.2016.53","journal-title":"Nat Rev Urol"},{"key":"4392_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/09638280701191743","volume":"30","author":"T Platz","year":"2008","unstructured":"Platz T, Vuadens P, Eickhof C, Arnold P, van Kaick S, Heise K (2008) REPAS, a summary rating scale for resistance to passive movement: item selection, reliability and validity. Disabil Rehabil 30:44\u201353. https:\/\/doi.org\/10.1080\/09638280701191743","journal-title":"Disabil Rehabil"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-020-04392-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T23:08:57Z","timestamp":1618182537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-020-04392-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,12]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4392"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04392-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,12]]},"assertion":[{"value":"13 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was obtained from the committee of \u201cFederico II\u201d University of Naples, Italy. The study included anonymized data collected in the clinical practice and was conducted in accordance with good clinical practice and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}